<DOC>
	<DOCNO>NCT00938626</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy follow treated T cell stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood store . High-dose chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This phase I trial study side effect best way give treat T cell follow stem cell transplant treat patient multiple myeloma .</brief_summary>
	<brief_title>Treated T Cells Followed Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To test feasibility safety infuse anti-CD3 x anti-CD20 bispecific antibody-armed activate T cell ( CD20Bi-AATC ) stem cell mobilization collection autologous peripheral blood stem cell transplantation ( PBSCT ) patient multiple myeloma . Secondary - To explore functional change immune cell population consequence immunotherapy test hypothesis CD20Bi-AATC induce anti-clonogenic myeloma precursor cell ( CMPC ) effect measure cytotoxicity ; serum cytokine level ; serum antibody titer myeloma cell pre-immunotherapy , immunotherapy , high-dose chemotherapy autologous PBSCT . - To explore whether infusion CD20Bi-AATC reduce proportion plasma cell CD20+ CMPC phenotype patient ' bone marrow assess multi-color flow cytometry immunotherapy . - To assess proportion bone marrow colony-forming assay induction salvage chemotherapy , pre-immunotherapy , post-immunotherapy determine whether infusion grossly affect bone marrow progenitor population . - To explore whether infusion CD20Bi-AATC induce B-cell defect cause immunoglobulin deficiency autologous PBSCT . - To measure immunoglobulin deficiency autologous PBSCT ( e.g. , quantitative IgG , IgM , IgA level number circulate T- B-cell subset ) . OUTLINE : After completion induction salvage chemotherapy , patient receive immunotherapy comprise anti-CD3 x anti-CD20-armed ATC IV weekly 2 week . At least 1-3 week second infusion , patient receive high-dose chemotherapy undergo autologous peripheral blood stem cell transplantation . Patients undergo leukapheresis G-CSF-mobilized autologous T-cells . Blood sample collect periodically evaluate antibody titer recall antigen ; serum IgG , IgM , IgA level ; proportion circulate B-cells phenotyping CD19 , CD20 , CD22 , CD23 , CD4 , CD8 , CD38 ; ability peripheral blood mononuclear cell kill multiple myeloma cell line patient 's cryopreserved myeloma cell via cytotoxicity assay ELISPOT assay ; human anti-mouse antibody responses murine IgG2a ( OKT3 ) . Bone marrow biopsy also collect analyze phenotype cell ( CD20+ , CD138- , CD27+ , CD22 , etc . ) via flow cytometry proportion plasma cell via flow cytometry hematoxylin-and-eosin staining . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Candidate highdose chemotherapy autologous stem cell transplantation No definite morphologic evidence myelodysplasia pretreatment bone marrow PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 70100 % ANC &gt; 500/mm^3 Platelet count ≥ 75,000/mm^3 Total bilirubin ≤ 2.0 mg/dL AST ALT ≤ 3 time upper limit normal Creatinine ≤ 2.0 mg/dL LVEF ≥ 45 % Corrected pulmonary diffusion capacity ≥ 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection severe medical problem adrenal dysfunction No active malignancy ( except nonmelanoma skin cancer ) require myelosuppressive chemotherapy radiotherapy No HIV infection PRIOR CONCURRENT THERAPY : See Disease Characteristics Onchemotherapy induction thalidomide lenalidomide dexamethasone allow No prior stem cell transplantation No 2 prior treatment regimen ( include one patient undergo leukapheresis Tcells ) No 4 course lenalidomide combination agent single agent 1year period No concurrent immunotherapy , radiotherapy , chemotherapy , antimyeloma therapy time antiCD3 x antiCD20armed ATC infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>